Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Idiopathic Hyposmia As a Preclinical Sign of Parkinson's Disease
Ann Neurol 56:173-181,169, Ponsen,M.M.,et al, 2004
Striatal Dopamine Trnasporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed tomography in Patients with Early Parkinson's Disease, Implications for a Preclinical Diagnosis
Arch Neurol 57:205-208, Schwarz,J.,et al, 2000
Clinical and[18F]dopa PET Findings in Early Parkinson's Disease
JNNP 59:597-600, Morrish,P.K.,et al, 1995
PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993
Preclinical Detection of Parkinson's Disease
Neurology Suppl 2, 41:5-921991., Koller,W.C.&Langston,J.W., 1991
Advances in Progressive Supranuclear Palsy: New Diagnostic Criteria, Biomarkers, and Therapeutic Approaches
Lancet Neurol 16:552-563, Boxer, A.L.,et al, 2017
Fat Embolism Syndrome Secondary to Bone Marrow Necrosis in Patients with Hemoglobinopathies
SMJ 109:549-553, Gangaraju, R.,et al, 2016
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Spinal Muscular Atrophy A Timely Review
Arch Neurol 68:979-984, Kolb, S.J.,et al, 2011
"Im fine; Im just waiting for my disease" The New and Growing Class of Presymptomatic Patients
Neurol 77:522-523, Kwon, J.M.et al, 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Superficial Siderosis
Arch Neurol 64:491-496, Kumar,J, 2007
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Motor Changes in Presymptomatic Huntington Disease Gene Carriers
Arch Neurol 53:487-492, Siemers,E.,et al, 1996